|
This is a promotional email intended for GB healthcare professionals only, sent on behalf of Gilead Sciences Ltd.
Prescribing information and adverse event reporting for YESCARTA® ▼(axicabtagene ciloleucel) can be found HERE.
|
|
|
|
| Did you miss our webinar: |
| “Evolving DLBCL Treatment: Practical Guidance to Optimise Patient Outcomes”? |
|
|
|
|
|
| (clicking these links takes you to a Gilead-owned website, www.kitecartforum.co.uk, which contains promotional content.) |
|
| Watch on the Kite CAR T Forum, renowned experts, Dr. Sridhar Chaganti, QE Birmingham, Dr. Kate Cwynarski, UCLH London, and Dr. Michael Jain, Moffitt Cancer Centre USA discuss how the treatment of DLBCL is changing, including YESCARTA in the 2L setting demonstrating superior OS compared to the SOCT. |
|
|
| www.kitecartforum.co.uk also serves as a valuable resource to help you stay up to date, informed and access other insightful discussions about CAR-T therapy. |
|
Redefine their storyline: YESCARTA ZUMA-7,
four-year OS analysis.
|
|
|
|
|
|
|
|
|
ZUMA-7 was a randomised, multicentre, Phase 3 trial of YESCARTA (n=180) vs SOCT (n=179) as 2L treatment in patients with R/R DLBCL. The primary endpoint was EFS, and key secondary endpoints were ORR and OS.3,4
In the primary analysis, median EFS was 8.3 months (95% CI: 4.5-15.8) and 2.0 months (95% CI: 1.6-2.8) for YESCARTA and SOCT, respectively (HR for event or death, 0.40; 95% CI: 0.31-0.51; p<0.001).4
The prespecified primary analysis of overall survival was recently published.1 |
|
|
The YESCARTA safety data from ZUMA-7 (n=170) showed:
|
| • |
The most significant and frequently occurring adverse reactions were CRS (92%), encephalopathy (49%) and infections (45%).
|
| • |
Serious adverse reactions occurred in 54% of patients.
|
| • |
The most common (≥5%) serious adverse reactions included CRS (17%), encephalopathy (16%), unspecified pathogen infections (8%), fever (6%) and viral infection (5%).
|
|
Please refer to the full Summary of Product Characteristics for full indication and safety information.
|
|
|
|
|
|
|
|
|
| (clicking this link takes you to a Gilead-owned website which contains promotional content) |
| Treatment with YESCARTA is now reimbursed via the CDF in England for adult patients with DLBCL and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.5
|
|
|
|
YESCARTA® is indicated for the treatment of adult patients with:3
|
| • |
diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy
|
| • |
relapsed or refractory (R/R) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy
|
| • |
R/R follicular lymphoma (FL) after three or more lines of systemic therapy
|
| References: |
| 1. |
Westin JR, et al. N Engl J Med 2023; doi: 10.1056/NEJMoa2301665. Online ahead of print.
|
| 2. |
Westin JR, et al. ASCO 2023 (late-breaking abstract #107.
|
| 3. |
YESCARTA Summary of Product Characteristics.
|
| 4. |
Locke FL, et al. N Engl J Med 2022;386:640–54 (and Supplementary Appendix).
|
| 5. |
Final appraisal document – Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B‑cell lymphoma after first-line chemoimmunotherapy. Issue date: April 2023. NICE 2023.
|
| Abbreviations: |
|
2L, second line; AE, adverse event; ASCT, autologous stem cell transplant; CAR T, chimeric antigen receptor T-cell; CI, confidence interval; COVID-19, coronavirus disease 2019; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival; FL, follicular lymphoma; HGBL, high-grade B-cell lymphoma; HR, hazard ratio; ORR, overall response rate; OS, overall survival; PMBCL, primary mediastinal large B-cell lymphoma; SOCT, standard of care therapy.
|
|
▼This medicinal product is subject to additional monitoring.
|
|
|
Adverse events should be reported. For Great Britain & Northern Ireland, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500. |
|
| Click here for YESCARTA Prescribing Information |
| UK-YES-0833 October 2023
|
 |
|
|
|
|
